Micreos, a Wageningen, Netherlands-based biotech company, secured €12m in equity funding.
The backers remained undisclosed.
The company will use the funds for the global development of Staphefekt™, its antibacterial lysin technology, as a pharmaceutical (Rx) product.
Led by CEO Mark Offerhaus, Micreos develops antibacterial solutions based on phage technology as a replacement for antibiotics in healthcare, veterinary medicine, the food processing industry and agriculture.
Staphefekt™ was launched in 2013 as the active compound in Gladskin, a a lysin (enzyme) based product for people with inflammatory skin conditions such as eczema, rosacea and acne.
The company, which has production facilities in Wageningen and Bilthoven, has a long-term cooperation with the Swiss technology institute ETH in Zürich.
It also markets FDA-approved Food Safety products including LISTEX™ (Listeria), and SALMONELEX™ (Salmonella) which are sold globally to food processing companies in the meat & poultry, cheese and fish industry.